Bioceres Crop Solutions Corp. (BIOX) is a company dedicated to enhancing agricultural output through a diverse range of solutions. Its operations are ...
Bioceres Crop Solutions Corp. (BIOX) is a fully integrated agricultural biotechnology platform focused on improving crop performance while supporting more resilient and sustainable agricultural systems. The company operates through three main segments: (1) Seed and Integrated Products, (2) Crop Protection, and (3) Crop Nutrition. In the Seed and Integrated Products ...Bioceres Crop Solutions Corp. (BIOX) is a fully integrated agricultural biotechnology platform focused on improving crop performance while supporting more resilient and sustainable agricultural systems. The company operates through three main segments: (1) Seed and Integrated Products, (2) Crop Protection, and (3) Crop Nutrition. In the Seed and Integrated Products segment, Bioceres works on seed technologies and genetic materials, including biotechnological innovations and specialized seed coatings. Its technology portfolio is often highlighted through HB4, a patented seed trait engineered for improved drought resistance, which is designed to help crops perform under water-stress conditions.
The Crop Protection segment complements the seed offering by formulating, manufacturing, and distributing crop protection products, including adjuvants, fungicide and insect-related solutions, weed control products, and related biological/chemical inputs such as pest lures and therapeutic-type agents. This segment is typically structured to be applied alongside cropping operations, enabling a more cohesive “from seed to protection” approach. Meanwhile, the Crop Nutrition unit develops, produces, and distributes inoculants, biostimulants, and fertilizers (including organic and micro-granular formats). Collectively, these offerings aim to enhance yields, crop vigor, and stress tolerance.
From a business model perspective, Bioceres’ integration across seed technologies and crop-input products creates opportunities for cross-selling and packaging of agronomic solutions that farmers can adopt throughout the growing season. The company also benefits from the learning loop between field performance (responses to drought, disease pressure, and soil conditions) and ongoing product development in its biotech and formulation capabilities.
Operationally, the “cost/BOM” structure in crop productivity businesses generally involves multiple input and production layers: seed trait/licensing and breeding-related development costs, manufacturing and formulation materials for crop protection (active ingredients, adjuvants, packaging, and quality controls), and biological/nutrition inputs (production, stabilization, and distribution). Bioceres’ integrated approach can influence costs by bundling capabilities (e.g., seed + protection + nutrition) and by leveraging scale in manufacturing/distribution, though it still faces typical agricultural-input risks such as seasonality, commodity-linked demand, and regional regulatory requirements.
Financially, directional metrics from the provided dataset show profitability pressure at the TTM snapshot (e.g., negative margins and negative returns on several profitability measures), alongside liquidity/working-capital dynamics. Even with investment in R&D (indicated by a positive research intensity to revenue ratio), the market valuation metrics suggest investors have expectations for future operational improvement rather than near-term earnings.
Key people include CEO Federico Trucco (serving since March 2019, per the provided information). Bioceres was founded in 2001 and is headquartered in Rosario, Argentina, with operations and commercialization presence across multiple countries, including Argentina, Uruguay, France, and South Africa.
Looking ahead, the company’s public positioning emphasizes productivity solutions intended to regenerate agricultural ecosystems and increase resilience in crops—supporting a transition of agriculture toward sustainability and, in its communications, carbon-neutral goals.
EPS estimate unavailable · Fiscal period ending 2026-06-30
D-4
5Y Trend (Revenue, Earnings, FCF)
Metric
Latest
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$333.3M
-28.3%
-48.2%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-55.4M
-1808.8%
+93.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+38.4%
-1.6%
-15.7%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-0.2%
-102.4%
-260.2%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-16.6%
-2482.8%
+87.0%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$35.3M
+86.4%
-100.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
+10.6%
+160.0%
-100.0%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
105.3%
+22.5%
+15.9%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
0.91x
-26.5%
-5.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Hello, everyone. Thank you for joining us, and welcome to Bioceres Crop Solutions Fiscal Third Quarter 2026 Financial and Operational Results Call. [Operator Instructions] I will now hand the conference over to Paula Savanti, Head of Investor Relations. Paula, please go ahead.
Paula Savanti: Thank you, and good morning, everyone. Welcome to Bioceres Crop Solutions Third Fiscal Quarter 2026 Earnings Conference Call. Our prepared remarks today will be led by our Chief Executive Officer, Federico Trucco; our General Counsel, Jose Roque; and our Chief Financial Officer, Ezequiel Simmermacher. All of them will be available for the Q&A session following the presentation. During this call, we will be making forward-looking statements. These statements are based on current expectations and assumptions that are subject to various risks and uncertainties. I refer you to the forward-looking statements section of the earnings release and presentation as well as the recent filings with the SEC. We assume no obligation to update or revise any forward-looking statements to reflect new or changed circumstances. In today's presentation, we will be making references to certain non-GAAP financial measures. Reconciliations of the non-GAAP measures can be found in our earnings press release. This conference call is being webcast, and the link is available at our Investor Relations website. It is now my pleasure to turn the call over to Federico.
Federico Trucco: Thanks, Paula, and good morning to everyone. Thanks for joining us today. Please turn to Slide 3 for today's key business and financial highlights. This quarter reflects a period of transition and operational refocusing for the company, while it is historically our weakest quarter from a baseline business perspective. Total revenues and gross profits showed a decline compared to the same quarter last year, which was partially offset by an improvement in operational expenses. Net loss was $10 million, primarily reflecting lower gross profit as well as increased financial expenses, all of which will be described in greater detail later in the presentation. Also, in the last 3 years, we have booked profits from IP rights and other commercial arrangements in this quarter, which helped us offset baseline operating losses. Although we continue to explore strategic arrangements with our partners on a regular basis and see these as a recurrent source of profitability, this year, the timing of profit-generating arrangements did not coincide with the initial months of the calendar year. As I have stated in my message to shareholders of March 16, we recognize the significance of the events surrounding Pro Farm and the uncertainty generated by the ongoing litigation process. Jose Roque, our General Counsel, will now provide an update of the ongoing litigation. Please turn to Slide 4.
Jose Roque: Thank you, Federico, and good morning to everyone on the call. As previously disclosed, in November 2025, 4 holders …
